MET inhibitors are now established TKIs in the treatment of NSCLC patients with exon 14 skipping mutation, which is present in 3–4% of patients with adenocarcinomas and 1–2% of patients with other histologies. The gene discussed is MET; the disease is adenocarcinoma.